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1. Introduction 
Vitamin D has been known as a regulator of bone and mineral metabolism by regulation of 
calcium absorption in the gut and reabsorption by the kidney, which is mediated by the 
vitamin D receptor (VDR). The expression of VDR in a variety of cell lines coupled with 
increased evidence of VDR involvement in cell differentiation and inhibition of cellular 
proliferation suggests that vitamin D plays a role in many diseases. A meta-analysis of 
randomized controlled trials demonstrated that intake of vitamin D supplements was 
associated with a significant 7% reduction in mortality from any causes (Autier & Gandini, 
2007). A serum 25-hydroxyvitamin D3 (25OHD3) concentration of 25 nmol/l was associated 
with a 17% reduction in incidence of cancer, a 29% reduction in total cancer mortality, and a 
45% reduction in digestive system cancer mortality (Giovannucci et al., 2006). A low serum 
25OHD3 was prospectively associated with an increased risk of fatal cancer in patients 
referred to coronary angiography (Pilz et al., 2008). 
Alphacalcidol, a vitamin D analogue, has been demonstrated significant antitumor activity 
in patients with low-grade non-Hodgkin’s lymphoma of the follicular, small-cleaved cell 
type (Raina et al., 1991). In patient with parathyroid cancer, vitamin D has been shown to 
avert or delay the progression of recurrence (Palmieri-Sevier et al., 1993). In locally 
advanced or cutaneous metastatic breast cancer, topical calcipotriol treatment reduced in the 
diameter of treated lesions that contained VDR (Bower et al., 1991). In a clinical trial, high-
dose calcitriol decreased Prostatic-specific antigen (PSA) levels by 50% and reduced 
thrombosis in prostate cancer patients (Beer et al., 2003 & 2006). In hepatocellular carcinoma, 
calcitriol and its analogs have been reported to reduce tumor volume, increase apoptosis of 
hepatocarcinoma cells by 21.4%, and transient stabilization of the serum alpha-fetoprotein 
levels (Dalhoff et al., 2003; Luo et al., 2004; Morris et al., 2002). 
Calcitriol additively or synergistically potentiates the antitumor of other types of 
chemotherapeutic agents. Calcitriol enhances cellular sensitivity of human colon cancer cells 
to 5-fluorouracil (Liu et al., 2010). Combination of calcitriol and cytarabine prolonged 
remission in elderly patients with acute myeloid leukemia (AML) and myelodysplastic 
syndrome (MDS) (Slapak et al., 1992; Ferrero, et al., 2004). In a prospective study, a 
combination of active vitamin D and ┙- interferon has shown to be effective in patients with 
metastatic renal cell carcinoma (Obara et al., 2008). Calcitriol promotes the anti-proliferative 
effects of gemcitabine and cisplatin in human bladder cancer models (Ma et al., 2010), and 
also potentiates antitumor activity of paclitaxel and docetaxel (Hershberger et al., 2001; Ting 
et al. 2007). A phase II study showed that high-dose calcitriol with docetaxel may increase 
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time to progression in patients with incurable pancreatic cancer when compared with 
docetaxel monotherapy (Blanke, 2009). 
2. Risk factors for the development of both vitamin D deficiency and cancer 
It has been noted that vitamin D and cancer share many of the same risk factors, including 
both environmental (air pollution, geographic and seasonal) and genetic risk factors. 
2.1 Environmental factors 
Changes in the environment, such as those caused by air pollution, geographic and seasonal 
factors, may cause diseases that contribute to the development of both vitamin D deficiency 
and cancer. 
2.1.1 Air pollution factors 
Atmospheric pollution has been suggested to be a cause of reduced vitamin D synthesis in 
the skin. In Australia, some authors demonstrated a large difference in vitamin D synthesis 
between an urban canyon (urbanized environment with tall building) and a typical 
suburban area (~2.5 km away from urban area) (Kinley et al., 2010). Increased atmospheric 
pollution may be related to haze from industrial and vehicle sources and lead to decrease in 
absorption of ultraviolet-B (UVB) photons, thereby reducing the cutaneous vitamin D 
synthesis (Mimms, 1996; Hollick, 1995). In another study, some reported that the higher 
atmospheric pollution, the lower the amount of UVB light reaching ground level (Agarwal 
et al., 2002). They also showed that children living in areas of high atmospheric pollution are 
at risk of developing vitamin D deficiency rickets. In a study Belgian postmenopausal 
women who participated in outdoor activities during the summer, urban inhabitants were 
reported to have an increased prevalence of vitamin D deficiency compared with rural 
inhabitants (Manicourt & Devogelaer, 2008). In a cross sectional study, living in a polluted 
area plays a significant independent role in vitamin D deficiency (Hosseinpanah et al., 2010). 
Similarly, cancer mortality rates (esophagus, stomach, colon-rectum, liver, lung, breast, and 
bladder) in 263 counties in all Provinces of China were inversely associated with solar UVB 
exposure by using the National Central Cancer Registries (NCCR) of China, satellite 
measurements of cloud-adjusted ambient UVB intensity that were obtained from the NASA 
Goddard Space Flight Center Data Archive Center database, and the Geographic 
Information System (GIS) methods (Chen et al., 2010). Cancer incidence rates (esophagus, 
stomach, colon-rectum, and cervix) in 30 counties were inversely correlated with ambient 
UVB exposure. Lung cancer mortality has been shown the strongest inverse correlation with 
an estimated 12% fall per 10 mW/(nm m2) increase in UVB irradiance even adjusted for 
smoking. These associations were similar to those observed in a number of populations of 
European origin. 
2.1.2 Geographic factors 
The relationship between the geographical variation of colon cancer mortality rates and 
vitamin D related to UVB was first proposed in 1980 (Garland & Garland, 1980). The authors 
showed that the colon mortality rates are highest in the Northeast and lowest in the 
Southwest of the United States from 1950 - 1969 and was correlated to the annual hours of 
sunshine. It has been observed that with each 10 degrees distance from equator, there is a 
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progressive decrease in UVB radiation exposure (Diffey, 1991). Solar UVB is the primary 
source of vitamin D for most people living on Earth. Nuclear submarine crewmen who were 
not exposed to UVB for 3 months showed a decrease in an already low circulating 25OHD3 
level from 13.7 to 7.9 ng/ml (Garland & Garland, 1980). Grant determined that 14 types of 
cancer (bladder, breast, colon, endometrial, esophageal, gallbladder, gastric, ovarian, 
pancreatic, rectal, renal and vulvar cancer and both Hodgkin’s and non-Hodgkin’s 
lymphoma) had mortality rates inversely correlated with solar UVB levels (Grant, 2009). 
During the cold weather, latitude was found to determine levels of vitamin D-producing UV 
radiation. As latitude increase, vitamin D producing UV radiation decreases dramatically 
and may inhibit vitamin D synthesis in humans (Kimlin et al., 2007). 
2.1.3 Seasonal factors 
Seasonal variations of 25OHD3 were reported either in southern and northern latitudes 
(Oliveri et al., 1993; Stryd et al., 1979). Another study confirmed and quantified the 
relatively large seasonal fluctuations in circulating 25OHD3 levels in association with 
summer sun exposure among outdoor workers. Their median serum 25OHD3 levels 
decreased from 122 nmol/L in late summer to 74 nmol/L in late winter (Barger-Lux & 
Heany, 2002). Similarly, a seasonal pattern has been noticed in many cancers with the 
highest in the winter and springs – including lung cancer, brain tumors, parathyroid tumor, 
non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, childhood leukemia/lymphoma, 
monocytic leukemia, breast cancer, thyroid cancer, bladder carcinoma, and cervical cancer. 
In the summer and autumn season, certain cancers (breast, colon, prostate, Hodgkin’s 
lymphoma, and lung) have a better survival rates than during other seasons (Luong & 
Nguyen, 2010). 
2.2 Genetic factors 
Genetic studies provide an excellent opportunity to link molecular variations with 
epidemiological data. DNA sequences variations such as polymorphisms have modest and 
subtle biological effects. Receptors play a crucial role in the regulation of cellular function, 
and small changes in their structure can influence intracellular signal transduction 
pathways.  
The VDR is expressed and regulated in mammary gland during the reproductive cycle 
(Zinser & Welsh, 2004). VDR ablation is associated with ductal ectasia of the primary ducts, 
loss of secondary and tertiary ductal branches and atrophy of the mammary fat pad (Welsh 
et al., 2011). VDR has also been demonstrated to be lowered in human colorectal 
adenocarcinoma biopsies (34.5%) than in adjacent normal mucosa (82.5%) (Meggouh et al., 
1990). In this colorectal adenocarcinoma, the incidence decreased from right colon (64.7%) to 
left colon (27.7%), and rectum (15%). Certain allelic variations in the VDR may also be 
genetic risk factors for developing tumors. There are five important common 
polymorphisms within the VDR gene region that are likely to exert functional effects on 
VDR expression. Cdx2, located in the promoter region of exon 1, affects the binding ability of 
VDR and subsequent VDR transcription activity; Fok1 located in translation start of the exon 
2; and three other variants (Bsm1, Apa1 and Taq1) located at the 3’ end of VDRs that may 
influence VDR expression by altering the mRNA stability. In a review of the literature, an 
association of VDR polymorphisms and cancer prognosis are reported to be strongest for 
prostate cancer (Fok1 and Taq1), breast cancer (Bsm1, Taq1 and Apa1), malignant melanoma 
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(Bsm1, Fok1 and Taq1), renal cell carcinoma (Taq1), colorectal cancer (Apa1, Fok1, Bsm1, and 
Taq1), epithelial ovarian cancer (Fok1), lung cancer (Taq1), and oral squamous cell carcinoma 
(Taq1) (Köstner et al., 2009; Mahmoudi et al., 2010; Slattery et al., 2001; Slattery et al., 2006; 
Taylor et al., 1996; Lundin et al., 1999; Hutchinson et al., 2000; Tamez et al., 2009; Dogan et 
al., 2009; Bektas-Kayhan et al., 2010). However, other reports are conflicting and the role of 
VDR polymorphisms remains obscure. Their studies revealed no relationship between 
prostate and breast cancers and VDR variants (Ntais et al., 2003; Császá & Abel, 2001; 
Newcomb et al., 2002; Buyru et al., 2003).  
There are numerous potential gene products that are transcriptionally activated by p53 and 
are involved in cell cycle arrest or apoptosis (Ko & Prives, 1996). Some authors 
demonstrated a trend toward lower risk of a p53 mutation with increased hours of sunshine 
exposure (Slattery et al., 2010). They also reported specific point mutations of the p53 gene 
were associated with the Fok1 and Cdx2 VDR genotypes. The p53 is one of the more 
commonly mutated genes in rectal and pancreatic tumors (Slattery et al., 2009; Slebos et al., 
2000). The mutated p53 gene increases the nuclear accumulation of VDR, even in the absence 
of added vitamin D, and converts vitamin D into an anti-apoptotic agent (Stambolsky et al., 
2010). 
The cytochrome P450 (CYP) is responsible for the oxidation, peroxidation, and/or reduction 
of vitamins, steroids, xenobiotics, and metabolism of drugs. The CYP27B1 (25-
hydroxyvitamin D3-1┙-hydroxylase) enzyme catalyzes the 1┙-hydroxylation of the 25OHD3 
to 1,25OHD3, the most active form of vitamin D3 metabolite. 1┙-hydroxylase is down-
regulated early in the neoplastic process of prostatic cancer cells (Chen et al., 2003; Hsu et 
at., 2001). In another study, the common genotypic variation in CYP27B1, however, has little 
or no effect on overall prostate cancer risk (Holt et al., 2009). The CYP27B1 mRNA in 
malignant breast tumors was reported to decrease in comparison with normal mammary 
tissue (McCarthy et al., 2009). 1┙-hydroxylation levels were found elevated in malignant 
pancreatic cells and their proliferation is inhibited by prohormone 25OHD3 (Schwartz et al., 
2004). Calcitriol significantly increased the 24-hydroxylase mRNA in the human cervical 
adenocarcinoma and the human ovarian adenocarcinoma cell lines (Kloss et al., 2010). The 
CYP24A1 encodes for the catabolic enzyme 24-hydroxylase and is responsible for 
inactivating vitamin D metabolites. The CYP24A1 gene was found to be amplified in breast 
cancer (Albertson et al., 2000). In prostate cancer mortality, significantly altered risks of 
recurrence/progression were observed in relation to genotype for two tagSNPs (single-
nucleotide polymorphisms) of VDR, CYP24A1, and one CYP27B1 (Holt et al., 2010); 
CYP24A1 expression is inversely correlated with promoter DNA methylation in prostate 
cancer cell lines (Luo et al., 2010), and its overexpression was also observed to be associated 
with poorer survival in patients with lung adenocarcinoma (Chen et al., 2011). The gene 
encoding for CYP24A1 and CYP27B1 have been observed to be expressed in colon cancer 
cells (Anderson et al., 2006; Tangpricha et al., 2001). Variants of CYP24A1 and CYP27B1 have 
also been reported to be associated with risk of distal colon cancer (Dong et al., 2009). There 
is a deregulation of the vitamin D signaling and metabolic pathways in breast cancer (Lopes 
et al., 2010). The VDR was strongly associated with the estrogen receptor positivity in breast 
carcinomas. CYP27B1 expression is slightly lower in invasive carcinomas (44.6%) than in 
benign lesions (55.8%). In contrast, CYP24A1 expression was augmented in carcinomas (56% 
in in situ and 53.7% in invasive carcinomas) when compared with that in benign lesions 
(19%). In another study, however, it has found no difference in the expression of the VDR, 
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CYP27B1, and CYP24A1 mRNA in breast cancer and non-neoplastic mammary tissue (de 
Lyra et al., 2006). 
Vitamin D binding protein (DBP) is the main transporter of vitamin D in the bloodstream. 
DBP-macrophage activating factor (DBP-maf) is considered to be deglycosylated DBP in 
cancer patients causing inability to activate macrophages and a strong inhibitory activity on 
prostate tumor cells (Rehder et al., 2009; Gregory et al., 2010). DBP-maf acts as a potent anti-
angiogenic factor and inhibits tumor growth in vivo (Kalkunte et al., 2005). These authors also 
reported that DBP-maf also inhibited the vascular endothelial growth factor (VEGF) signaling.  
3. Role of vitamin D and its analog in cancer 
Calcitriol acts mainly via its high affinity receptor VDR through a complex network of 
genomic (transcription and post-transcription), binds to intracellular VDR, which 
subsequently heterodimerizes with another nuclear retinoid X receptor (RXR) and non-
genomic mechanisms which may indirectly affect gene transcription via the regulation of 
intracellular signaling pathways that target transcription factors. VDR expressed has been 
detected in a variety of cultured human cell lines. In breast cancer, the protein levels of the 
VDR were elevated in sensitive cell lines upon 1,25OHD3 treatment, whereas resistant clones 
were unable to induce VDR (Jensen et al., 2002). The authors suggested that the levels of 
VDR in cancer might serve as a prognostic marker in cancer treatment with 1,25OHD3.  
Calcitriol is a potent regulator of cell proliferation, differentiation and apoptosis in a variety 
of cell types. Calcitriol and its analogs induce apoptosis in tumor cells through the activation 
of a caspase cascade (Guzey et al., 2002; Weitsman et al., 2003). The caspases have been 
considered the pivotal executioner of all programmed cell death (Hengartner, 2000). 
However, calcitriol may induce apoptosis in cancer cells through another novel cascade- and 
p53-independent pathway that can be inhibited by Bcl-2 (Mathiasen et al., 1999). Calcitriol 
and its analogs may cause apoptosis in cancer cells directly by increasing intracellular free 
calcium ([Ca2+]i) (Vandewalle et al., 1995) and indirectly through the activation of a 
calcium-dependent cysteine protease, µ-calpain (Berry et al., 1999; Mathiasen et al., 2002). 
Furthermore, calcitriol stimulates membrane phospho-inositide breakdown in human colon 
cancer cell line, causing translocation of protein kinase C to the membrane, and increasing 
[Ca2+]i by both releasing calcium stores and promoting calcium influx (Wali et al., 1992). 
Calcitriol and it analogs are potent inducers of both active and latent forms of transforming 
grow factor beta (TGF┚), which participates in the regulation of cell growth, phenotype, and 
differentiation in various tissues (Koli & Keski-Oja, 1995; Laiho & Keski-Oja, 1992).  
Calcitriol has been shown to mediate a G2/M cell cycle progression and induce cell death in a 
number of cancer cell lines via direct induction of GADD45α, which is a DNA-induced and 
p53-regulated gene that plays an essential role in cell cycle control and DNA repair (Jiang et 
al., 2003; Akutsu et al., 2001). By contrast, the anti-proliferative functions of VDR are 
associated at the G0/G1 stage of the cell cycle, coupled with upregulation of a number of cell 
cycle inhibitors, kinase inhibitors p21(waf1/cip1) (Saramäki et al., 2006). However, paricalcitol 
arrested in G1/G0 phases and G2/M phases in leukemia cell lines, in G1G0 in myeloma cells, 
and induced the expression of p21(waf1/cip1) and p27(Kip1), and down –regulation of p45SKP2 
(Wang et al., 1996; Munker et al., 1996; Jiang et al., 1994; Lin et al., 2003). 
Angiogenesis has been suggested as an indicator of neoplastic transformation. Calcitriol has 
been reported a potent inhibitor of tumor cell-induced angiogenesis (Shokravi et al., 1995; 
Majewski et al., 1996). Calcitriol inhibits hypoxia inducible factor-1(HIF-1)/VEGF pathway 
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in human cancer cells (Ben-Shoshan et al., 2007). Increased levels of HIF-1 activity are often 
associated with increased tumor aggressiveness, therapeutic resistance, and mortality 
(Semenza, 2003). VEGF stimulates endothelial cells to proliferate, migrate, and organize into 
capillary beds (Polverini et al., 2002). DBP-maf inhibited VEGF signaling by decreasing 
VEGF-mediated phosphorylation of VEGFR-2 and ERK1/2, a downstream target of the 
VEGF signaling cascade (Kalkunte et al., 2005). Calcitriol and its analogs have been 
demonstrated to inhibit tumor invasion and metastasis by reducing the expression of serine 
proteinases, metalloproteinases (MMP-2 and MMP-9), VEGF and parathyroid hormone 
related peptide (PTHrP) in lung carcinoma cell lines (LLC-GFP cells) (Nakagawa et al., 
2005a). The metastatic growth of LLC-GFP cells was remarkably reduced in response to 
calcitriol (Nakagawa et al., 2005b).  
Calcitriol and its analogs induced the expression of tumor suppressor gene PTEN 
(phosphatase and tensin homolog deleted on chromosome 10) (Liu et al., 2005; Kumagai et 
al., 2003). Overexpression of VDR stimulated the activity of PTEN promoter and also 
enhances the PTEN protein level (Pan et al., 2009). The PTEN phosphatase can block 
phosphoinositide 3-kinase/AKT (PI3K/Akt) signaling pathway, which contribute to both 
cell death and the inhibition of cell proliferation (Cantley & Neel, 1999). PTEN mutations 
have been found in many human cancers (Tamura et al., 1999). In colon cancer cells, 
calcitriol and its analogs increase the expression of E-cadherin, a transmembrane protein 
located in intercellular adherent junctions, which make cells more adherent to each other 
(Pálmer et al., 2001). Loss of E-cadherin expression is a common even during the transition 
from adenoma to carcinoma (Perl et al., 1998). E-cadherin is a tumor suppressor gene, and its 
decrease in expression is associated with poor prognosis in patients with prostate cancer 
(Umbas et al., 1994). Vitamin D also suppresses tenascin-C, which promotes growth, 
invasion, and angiogenesis during tumorigenesis (Gonzȧlez-Sancho et al., 1998).  
The induction of ornithine decarboxylase (ODC) may be an essential process in the 
mechanism of tumor promotion (O’brien et al., 1975), and calcitriol has been reported to 
inhibit tumor promoter-induced ODC expression in the skin, stomach, colon, and liver in 
animals (Hashiba et al., 1987). Calcitriol, however, did not induce epidermal ODC activity, 
but inhibited the induction of ODC by the tumor promoters 12-0-tetradecanoylphorbol-13-
acetate (TPA) and teleocidin, suggesting that it is an anti-promoter rather than a promoter in 
mouse skin carcinogenesis (Chida et al., 1984).  
Calcitriol has been reported to regulate the transcription of the tumor necrosis factor alpha 
(TNF-┙) without affecting translation in leukemia cell line (Steffen et al, 1988), may increase 
the sensitivity of cancer cells to TNF-┙ and potentiates the cytotoxic effect of the cytokine 
(Yacobi et al., 1996), which is an important factor in immunological anti-cancer therapy. 
TNF-┙ potentiates the effect of 1,25OHD3 in inducing of differentiation of human myeloid 
cell lines (Trinchieri et al., 1987). 
Prostaglandins (PGs) have been shown to play a role in the development and progression of 
many cancers. Calcitriol has been reported to regulate the expression of several key genes 
involved in the PG pathway causing a decrease in PG synthesis (Moreno et al., 2005). 
Cyclooxygenase (COX) participates in the conversion of arachidonic acid to PGs. COX-2 has 
been reported to increase in various malignancies (van Rees et al., 2001; Ristimaki et al., 
2002). Calcitriol and its analogs decreased expression of COX-2 in colon cancer cells 
(Kumagai et al., 2003). Selective COX-2 inhibitor reduces the polyp in patients with familial 
adenomatous polyposis (Steinbach et al., 2000). 15-hydroxy-prostaglandin dehydrogenase 
(15-PGDH) is the enzyme that catalyzes the conversion of PGs to their corresponding 15-
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keto derivatives; 15-PGDH has been demonstrated as an oncogene antagonist and plays a 
tumor-suppressive role in colon cancer (Yan et al., 2004). Calcitriol increases 15-PGDH 
mRNA and protein expression in various prostate cancer cells (Moreno et al., 2005). 
Calcitriol has also found to regulate COX-2 and 15-PGDH expression in other cells (Pichaud 
et al., 1997; Aparna et al., 2008). Calcitriol and its analogs can significantly decrease 
intestinal tumor load in ApcMin mice (Huerta et al., 2002). Vitamin D and its metabolites have 
been known to inhibit cell proliferation in human rectal mucosa and a colon cancer cell line 
(Thomas et al., 1992). 
The human peroxisome proliferator-activated receptor delta (PPARδ) and VDR signaling 
pathways regulate a multiple of genes that are of importance for a multiple of cellular 
functions including cell proliferation, cell differentiation, immune response and apoptosis. The 
provided link between VDR and PPAR may play an important role in treatment in prostate 
cancer and melanoma (Peehl & Feldman, 2004; Sertznig et al., 2009). PPARδ expression was 
reported to be increased by 1.5–3.2-fold after a 3-h stimulation of breast and prostate cancer 
cell lines with 1,25OHD3 (Dunlop et al., 2005). PPARδ has been reported to regulate lung 
cancer cell growth (Fukumoto et al., 2005) and it also may attenuate colon and skin 
carcinogenesis (Hartman et al., 2004; Marin et al., 2006; Kim et al., 2004). In addition, PPARδ 
deficiency does not suppress intestinal tumorigenesis in ApcMin/+ mice (Reed et al., 2004). 
Hypercalcemia is a common complication of paraneoplastic syndromes and is a contributor 
to the morbidity of cancer patients; in most cases, hypercalcemia is mediated by PHTrP. The 
PTHrP production has been suppressed by 1,25OHD3 and its analogs in cancer cell line via 
down-regulation and suppression of epidermal growth factor (ECF)-induced PTHrP gene 
expression (Kremer et al., 1996; Kunakornsawat et al., 2002; Fazon et al., 1998). Calcitonin 
has been known to secrete in response to high calcium level and C cell of the human 
medullary carcinoma and was suppressed by calcitriol (Telenius-Berg et al., 1975; Zabel & 
Dietel, 1991). 
4. Conclusion 
Vitamin D certainly has a role in the prevention and treatment of cancer. It is necessary to 
check serum 25OHD3 and parathyroid hormone (PTH) status in cancer patients. Serum 
levels of PTH have been reported to correlate with PSA levels and colorectal cancer (Skinner 
& Schwartz, 2009; Charalampopoulos et al., 2010). Some authors proposed that, in patients 
with normal calcium levels, the serum 25OHD3 levels should be stored to > 55ng/ml in 
cancer patients (colon, breast, and ovary) (Garland et al., 2007). Calcitriol, 1,25OHD3, is best 
used for cancer treatment, because of its active form of vitamin D3 metabolite, suppression 
of PTH levels (acted as cellular growth factor), and their receptors presented in most of 
human cells. However, monitor of serum 25OHD3 after taking calcitriol is not necessary 
because calcitriol inhibits the production of serum 25OHD3 by the liver (Bell et al., 1984; 
Luong & Nguyen, 1996). The main limitation to the clinical widespread evolution of 
1,25OHD3 is its hypercalcemic side-effects.  
5. References 
Agarwal, KS; Mughal, MZ; Upadhyay, P; et al. (2002). The impact of atmostpheric pollution 
on vitamin D status of infants and toddlers in Delhi, India. Arch Dis Child. Vol.87, 
pp.111-113. 
www.intechopen.com
 
Advances in Cancer Management 
 
8 
Anderson, MG; Nakane, M; Ruan, X; et al. (2003). Expression of VDR and CYP24A1 mRNA 
in human tumors. Cancer Chemother Pharmacol. Vol.57, pp.234-240. 
Albertson, DG; Ylstra, B; Segraves, B; et al. (2000). Quantitative mapping of amplicon 
structure by array CHG identifies CYP24 as a candidate oncogene. Nat Genet. 
Vol.25, pp.144-146. 
Aparna, R; Subhashini, J; Roy, KR; et al. (2008). Selective inhibition of cyclooxygenase-2 
(COX-2) by 1alpha-,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin 
D analog. J Cell Biochem. Vol.104, pp.1832-1842. 
Autier, P and Gandini, S (2007).Vitamin D supplementation and total mortality: a meta-
analysis of randomized controlled trials. Arch Intern Med. Vol.167, pp.1730-1737. 
Barger-Lux, MJ; Heany, RP. (2002). Effects of above average summer sun exposure on serum 
25-hydroxyvitamin D and calcium absorption. J Clin Endocrinol Metab. Vol.87, 
pp.4952-4956. 
Beer, TM; Lemmon, D; Lowe, BA; et al. (2003). High-dose weekly oral calcitriol in patients 
with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 
Vol.97, pp.1217-1224. 
Beer, TM; Venner, PM; Ryan, CW; et al. (2006). High dose calcitriol may reduce thrombosis 
in cancer patients. Br J Hematol. Vol.135, pp.392-394. 
Bektas-Kayhan, K; Unür, M; Yaylim-Eraltan, I; et al. (2010). Association of vitamin D 
receptor Taq1 polymorphism and susceptibility to oral squamous cell carcinoma. In 
Vivo. Vol.24, No.5, pp.755-759. 
Ben-Shoshan , M; Amir, S; Dang, DT; et al. (2011). 1┙,25-dihydroxyvitamin D3 (calcitriol) 
inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in 
human cancer cells. Mol Cancer Ther. Vol.6, No.4, pp.1433-1439. 
Bell, NH; Shaw, S; and Turner, RT. (1984). Evidence that 1,25-dihydroxyvitamin D3 inhibits 
the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest. Vol.74, 
pp.1540-1544. 
Berry, DM and Meckling-Gill, KA. (1999). Vitamin D analogs, 20-epi-22-oxa-24a,26a,27a-
trihomo-1┙,25(OH)2-vitamin D3, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin D3 and 
1┙,25(OH)2-lumisterol3 prime NB4 leukemia cells for monocytic differentiation via 
nongenomic signaling pathways, involving calcium and calpain. Endocrinology. 
Vol.140, pp.4779-4488. 
Blanke, CD; Beer, TM; Todd; et al. (2009). Phase II study of calcitriol-enhanced docetaxel in 
patients with previously untreated metastatic or locally advanced pancreatic 
cancer. Investigational New Drugs. Vol. 27, No.4, pp.374-378. 
Bower, M; Colston, KW; Stein, RC; et al. (1991). Topical calcipotriol treatment in advanced 
breast cancer. Lancet. Vol.337, No.8743, pp.701-702. 
Buyru, N; Tezol, A; Yosonkaya-Fenerci, E; Dalay, N. (2003). Vitamin D receptor gene 
polymorphisms in breast cancer. Exp Mol Med. Vol.35, pp.550-555. 
Cantley, LC and Neel, BG. (1999). New insights into tumor suppression: PTEN suppresses 
tumor formation by restraining the phosphinositide 3-kinase/AKT pathway. Proc 
Natl Acad Sci USA. Vol.96, pp.4240-4245. 
Charalampopoulos, A; Charalabopoulos, A; Batistatou, A; et al. (2010). Parathormone and 
1,25(OH)2D3 but not 25(OH)D3 serum levels, in an inverse correlation, reveal an 
association with advanced stages of colorectal cancer. Clin Exp Med. Vol.10, pp.69-
72. 
www.intechopen.com
 
Vitamin D and Cancer 
 
9 
Chen, TC; Wang, L; Whitlatch, LW; et al. (2003). Prostatic 25-hydroxyvitamin D-1alpha-
hydroxylase and its implication in prostate cancer. J Cell Biochem. Vol.88, pp.315-
322. 
Chen, W; Clements, M; Rahman, B; et al. (2010). Relationship between cancer 
mortality/incidence and ambient ultraviolet B irradiance in China. Cancer Causes 
Control. Vol.21, No.10, pp.1701-1709. 
Chen, G; Kim,  SH; King, AN; et al. (2011). CYP24A1 is an independent prognostic marker of 
survival in patients with lung adenocarcinoma. Clin Cancer Res. Vol.17, No.4, 
pp.817-826. 
Chida, K; Hashiba, H; Suda, T; et al. (1984). Inhibition by 1┙,25-dihydroxyvitamin D3 of 
induction of epidermal ornithine decarboxylase caused by 12-0-
tetradecanoylphorbol-13-acetate and teleocidin B. Cancer Res. Vol.44, pp.1387-1391. 
Császá, A and Abel, T. (2001). Receptor polymorphisms and diseases. Eur J Pharmacol.  
Vol.414, pp.9-22. 
de Lyra, EC; da Silva, IA; Katayama, ML; et al. (2006). 25(OH)2D3 serum concentration and 
breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and vitamin D 
receptor in women with and without breast cancer. J Steroid Biochem Mol Biol. 
Vol.100, No.4-5, pp.184-192. 
Dalhoff, K; Dancey, J; Astrup, L; et al. (2003). A phase II study of the vitamin D analogue 
Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer. Vol.89, 
pp252-257. 
Diffey, BL. (1991). Solar ultraviolet radiation effects on biologic systems. Phys Med Biol. 
Vol.36, pp.299-328. 
Dogan, I; Onen, HI; Yurdakul, AS; et al. (2009). Polymorphisms in the vitamin D receptor 
gene and risk of lung cancer. Med Sci Monit. Vol.15, No.8, pp.BR232-242. 
Dong, LM; Ulrich, CM; Hsu, L; et al. (2009). Vitamin D related genes, CYP24A1 and 
CYP27B1, and colon cancer risk. Cancer Epidemiol Biomakers Prev. Vol.18, No.9, 
pp.2540-2548. 
Dunlop, TW; Väisänen, S; Frank, C; et al. The peroxisome proliferator-activated receptor 
delta gene is a primary target of 1┙,25-dihydroxyvitamin D3 and its nuclear 
receptor. J Mol Biol. Vol.349, pp.248-260. 
Falzon, M; and Zong, J. (1998). The noncalcemic vitamin D analogs EB 1089 and 22-
oxacalcitriol suppress serum-induced parathyroid hormone-related peptide gene 
expression in a lung cancer cell line. Endocrinology. Vol.139, pp.1046-1053. 
Ferrero, D; Campa, E; Dellacasa, C; et al. (2004). Differentiating agents + low-dose 
chemotherapy in the management of old/poor prognosis patients with acute 
myeloid leukemia or myelodysplastic syndrome. Haematologica. Vol.89, pp.619-620. 
Fukumoto, K; Yano, Y; Virgona, N; et al. (2005). Peroxisome proliferator-activated receptor 
delta as a molecular target to regulate lung cancer cell growth. FEBS Lett. Vol.579, 
pp.3829-3836. 
Garland, CF and Garland, FC. (1980). Do sunlight and vitamin D reduce the likelihood of 
colon cancer? Int J Epidemiol. Vol.9, pp.227-231. 
Garland, CF; Grant, WB; Mohr, SB; et al. (2007). What is the dose-response relationship 
between vitamin D and cancer risk? Nutr Rev. Vol.65, No.8, Pt.2, pp.S91-S95 
www.intechopen.com
 
Advances in Cancer Management 
 
10
Giovannucci, E; Liu, Y; Rimm, EB; et al. (2008). Prospective study of predictors of vitamin D 
status and cancer incidence and mortality in men. J Natl Cancer Inst. Vol.98, pp.451-
459. 
Gonzȧlez-Sancho, JM; Alvarez-Dolado, M; Muñoz, A. (1998). 1,15-dihydroxyvitamin D3 
inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. Vol.426, 
pp.225-228.  
Grant,WB. ((2009). How strong is the evidence that solar ultraviolet B and vitamin D reduce 
the risk of cancer. Dermato-Endocrinology. Vol.1, No.1, pp.17-24. 
Gregory, KJ; Zhao, B; Bielenberg, DR; et al. (2010). Vitamin D binding protein-macrophage 
activating factor directly inhibits proliferation, migration, and uPAR expression of 
prostate cancer cells. PLos One. Vol.5, No.10, p.213428. 
Guzey, M; Kitada, S; Reed, JC; et al. (2002). Apoptosis induction by 1alpha,25-
dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther.  Vol.1, pp.667-677. 
Hartman, FS; Nicol, CJ; Marin, HE; et al. (2004). Peroxisome proliferator-activated receptor 
delta attenuates colon carcinogenesis. Nat Med. Vol.10, pp.481-483. 
Hashiba, H; Fukushima, M; Chida, K; et al. (1987). Systemic inhibition of tumor promoter-
induced ornithine decarboxylase in 1┙,25-dihydroxyvitamin D3-treated animals. 
Cancer Res. Vol.47, pp.5031-5035. 
Hengartner, MO. (2000). The biochemistry of apoptosis. Nature. Vol.407, pp.770-776. 
Hershberger, PA; Yu, WD; Modzelewski, RA; et al. (2001). Calcitriol (1,25-
dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in 
vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. Vol.7, pp.1043-
1051. 
Hollick, MF. (1995), Environmental factors that influence the cutaneous production of 
vitamin D. Am J Clin Nutr. Vol.61(suppl), pp.638S-645S. 
Holt, SK; Kwon, EM; Peters, U; et al. (2009). Vitamin D pathway gene variants and prostate 
cancer risk. Cancer Epidemiol Biomarkers Prev. Vol.18, No.6, pp.1928-1933. 
Holt, SK; Kwon, EM; Koopmeiners, JS; et al. (2010). Viamin D pathway gene variants and 
prostate cancer prognosis. Prostate. Vol.70, No.13, pp.1448-1460. 
Hosseinpanah, F; Hashemi pour, S; Heibatollahi. M; et al. (2010). The effects of air pollution 
on vitamin D status in healthy women: A cross section study. BMC Pub Health. 
Vol.10, p.519. 
Hsu, JY; Feldman, D; McNeal, JE; et al. (2001). Reduced 1alpha-hydroxylase activity in 
human prostate cancer cells correlates with decreased susceptibility to 25-
hroxyvitamin D3-induced growth inhibition. Cancer Research. Vol.61, pp.2852-2856. 
Huerta, S; Irwin, RW; Heber, D; et al. (2002). 1alpha,25(OH)2-D3 and its synthetic analogue 
decrease tumor load in the Apcmin mouse. Cancer Res. Vol.62, No.1, pp.741-746. 
Hutchinson, PE; Osborne, JE; Lear, JT; et al. (2000). Vitamin D receptor polymorphisms are 
associated with altered prognosis in patients with malignant melanoma. Clin Cancer 
Res. Vol.6, pp.498-504. 
Jiang, H; Lin, J, Su, ZZ; et al. (1994). Induction of differentiation in human promyelotic HL-
60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. 
Oncogene. Vol.9, pp.3397-3406. 
Jensen, SS; Madsen, MW; Lucas, J; et al. (2002). Sensitivity to growth suppression by 
1alpha,25-dihydroxyvitamin D3 among MCF clones correlates with vitamin D 
receptor protein induction. (2002). J Steroid Biochem Mol Biol. Vol.81, pp.123-133. 
www.intechopen.com
 
Vitamin D and Cancer 
 
11 
Kalkunte, S; Brard, L; Granai, CO; Swamy, N. (2005). Inhibition of angiogenesis by vitamin-
D binding protein: characterization of anti-endothelial activity of DBP-maf. 
Angiogenesis. Vol.8, pp.349-360. 
Kim, DJ; Akiyama, TE; Hartman, FS; et al. (2004). Peroxisome proliferator-activated receptor 
beta (delta)-dependent regulation of ubiquitin C expression contributes to 
attenuation of skin carcinogenesis. J Biol Chem. Vol.279, pp.23719-23727.  
Kimlin, MG; Olds, WJ; Moore, MR. (2007). Location and vitamin D synthesis: is the 
hypothesis validated by geographical data? J Phochem Photobiol B. Vol.86, pp.234-
239. 
Kinley, AM; Janda, M; Auster, J; Kimlin, M. (2010). In vitro model of vitamin D synthesis by 
UV radiation in an Australian urban environment. Photochem Photobiol. First 
published online: 2010 Dec 22. DOI: 10.1111/j.1751-1097.2010.00865.x 
Kloss, M; Fischer, D; Thill, M; et al. (2010). Vitamin D, calcidiol and calcitriol regulate 
vitamin D metabolizing enzymes in cervical and ovarian cancer cells. Anticancer 
Res. Vol.30, No.11, pp.4429-4434. 
Ko, LJ and Prives, C. (1996). p53: puzzle and paradigm. Genes Dev. Vol.10, pp.1054-1072. 
Koli, K and Keski-Oja, J. (1995). 1,25-dihroxyvitamin D3 enhances the expression of 
transforming growth factor ┚1 and its latent form binding protein in cultured 
breast carcinoma cells. Cancer Res. Vol.55, pp.1540-1546.  
Köstner, K; Denzer, N; Müller, CS; et al (2009). The relevance of vitamin D receptor (VDR) 
gene polymorphisms for cancer: a review of the literature. Anticancer Res. Vol.29, 
No.9, pp.3511-3536. 
Kremer, R; Shustik, C; Tabak, T; et al. (1996). Parathyroid-hormone-related peptide in 
hematologis malignancies. Am J Med. Vol.100, No.4, pp.406-411. 
Kumagai, T; O’Kelly, J; Said, JW; et al. (2003). Vitamin D2 analog 19-nor-1,25-dihroxyvitamin 
D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl 
Cancer Inst. Vol.95, No.12, pp.896-905. 
Kunakornsawat, S; Rosol, TJ; Capen, CC; et al. (2002). Effects of 1,25-dihydroxyvitamin D3 
[1,25(OH)2D3] and its analogs (EB1089 and analog V) on canine adenocarcinoma 
(CAC-8) in nude mice. Biol Pharm Bull. Vol.25, pp.642-647. 
Ma, Y; Yu, WD; Trump, DL; et al. (2010). Enhances antitumor activity of gemcitabine and 
cisplatin in human bladder cancer models. Cancer. Vol.116, pp.3294-3303. 
Mahmoudi, T; Mohebbi, SR; Pourhoseingholi, MA; et al. (2010). Vitamin D receptor gene 
Apa1 polymorphism is associated with susceptibility to colorectal cancer. Dig Dis 
Sci. Vol.55, No.7, pp.2008-2013. 
Majewski, S; Skopinska, M; Marczak, M; et al. (1996). Vitamin D3 is a potent inhibitor of 
tumor cell-induced angiogenesis.  J Invest Dermatol Symp Proc. Vol.1, No.1, pp.97-
101. 
Manicourt, DH and Devogelaer, JP. (2008). Urban tropospheric ozone increases the 
prevalence of vitamin D deficiency among Belgian postmenopausal women with 
outdoor activities during summer. J Clin Endocrinol Metab. Vol.93, pp.3893-3899. 
Marin, HE; Peraza, MA; Billin, AN; et al. (2006). Ligand activation peroxisome proliferator-
activated receptor delta inhibits colon carcinogenesis. Cancer Res. Vol.66, pp.4394-
4401. 
www.intechopen.com
 
Advances in Cancer Management 
 
12
Mathiasen, IS; Lademann, U; Jäättelä, M. (1999). Apoptosis induced by vitamin D 
compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known 
caspases or p53. Cancer Res. Vol.59, pp.4848-4856. 
Mathiasen, IS; Sergeev, IN; Bastholm, L; et al. (2002). Cacium and caplain as key mediators 
of apoptosis-like death induced by vitamin D compounds in creast cancer cells. J 
Biol Chem. Vol.277, pp.30738-30745. 
McCarthy, K; Laban, C; Bustin, SA; et al. (2009). Expression 25-hydroxyvitamin D3-1┙-
hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. 
Anticancer Res. Vol.29, No.1, pp.155-157. 
Meggouh, F; Lointier, P; Pezet, D; Saez, S. (1990). Evidence of 1,25-dihydroxyvitamin D3 in 
human digestive mucosa and carcinoma tissue biopsies taken at different levels of 
the digestive tract, in 152 patients. J Steroid Biochem. Vol.36, No.1-2, pp.143-147. 
Mims, FM 3rd. (1996). Significant reduction of UVB caused by smoke from biomass burning 
in Brazil. Photochem Photobiol. Vol.64, pp.814-816. 
Moreno, J; Krishnan, AV; Swami, S; et al. (2005). Regulation of prostaglandin metabolism by 
calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. Vol.65, 
pp.7917-7925. 
Morris, DL; Jourdan, JL; Finlay, I; et al. (2002). Hepatic intra-arterial injection of 1,25-
dihydroxyvitamin D3 in lipiodol: pilot study in patients with hepatocellular 
carcinoma. Int J Oncol. Vol.21, pp.901-906. 
Munker, R; Kobayashi, T; Elstner, E; et al. (1996). A new series of vitamin D analogs is 
highly active for clonal inhibition, differentiation, and induction of WAF1 in 
myeloid leukemia. Blood. Vol.88, pp.2201-2209. 
Nakagawa, K; Sasaki, Y; Kato, S; et al. (2005a). 22-Oxa-1alpha-25-dihydroxyvitamin D3 
inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. Vol.26, pp.1044-
1054. 
Nakagawa, K; Kawaura, A; Sato, S; et al. (2005b). 1 alpha,25dihydroxyvitamin D3 is a 
preventive factor in the metastasis of lung cancer. Carcinogenesis. Vol.26, pp. 294-
440. 
Newcomb, PA;Kim, H;Trentham-Dietz, A; et al. (2002). Vitamin D receptor polymorphism 
and breast cancer risk. Cancer Epidemiol Biomarkers Prev. Vol.11, pp.1503-1504. 
Ntais, C; Polycarpou, A; Ioannidis, JP. (2003). Vitamin D receptor gene polymorphisms and 
risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. Vol.12, 
pp.1395-1402. 
Laiho, M and Keski-Oja, J. (1992). Transforming growth factor-┚: as regulators of cellular 
growth and phenotype. CRC Crit Rev Oncogenesis. Vol.3, pp.1-26. 
Lin, R; Wang, TT; Miller, WH; et al. (2003). Inhibition of F-Box protein p45SKP2 expression 
and stabilization of cyclin-dependent kinase inhibitor p27KIP1 in vitamin D analog-
treated cancer cells. Endocrinology. Vol.144, pp.749-753. 
Liu, W; Asa, SL; Ezzat, S. (2005).  1┙,25-dihydroxyvitamin D3 target PTEN-dependent 
fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol. 
Vol.19, pp.2349-2357. 
Liu, G; Hu, X; Chakrabarty, S; et al. (2010). Vitamin D mediates its action in human colon 
carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates 
malignant cell behavior and the expression of thymidylate synthase and surviving 
and promotes cellular sensitivity to 5-FU. Int J Cancer. Vol.126, pp.631-639. 
www.intechopen.com
 
Vitamin D and Cancer 
 
13 
Lopes, N; Sousa, B; Martins, D; et al. (2010). Alterations in vitamin D signaling and 
metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and 
CYP24A1 expression in benign and malignant breast lesions vitamin D pathways 
unbalanced in breast lesions. BMC Cancer. Vol.10, p.483. 
Lundin, AC; Söderkvist, P; Erichsson, B; et al. (1999). Association of breast cancer 
progression with a vitamin D receptor gene polymorphism. Cancer Res. Vol.59, 
pp.2332-2334. 
Luo, WJ; Chen, JY; Xu, W; et al. (2004). Effects of vitamin D analogue EB1089 on 
proliferation and apoptosis of hepatic carcinoma cells. Zhonghua Yu Fang Yi Xue Za 
Zhi. Vol.38, pp.415-418. [article in Chinese] 
Luo, W; Karpf, AR; Deeb, KK; et al. (2010). Epigenetic regulation of vitamin D 24-
hydroxylase/CYP24A1 in human prostate cancer. Cancer Res. Vol.70, No.14, 
pp.5953-5962. 
Luong, VQK and Nguyen, THL. (1996). Coexisting hyperparathyroidism and primary 
hyperparathyroidism with vitamin D-deficient osteomalacia in a Vietnamese 
immigrant. Endocrine Practice. Vol.2, pp.250-254. 
Luong, VQK and Nguyen, THL. (2010). The beneficial role of vitamin D and its analogs in 
cancer treatment and prevention. Crit Rev Oncology/Hematology. Vol.73, pp.192-201. 
O’Brien, TG; Simsiman, RC; Boutwell, RK. (1975). Induction of the polyamine-biosynthetic 
enzymes in mouse epidermis and their specificity for tumor promotion. Cancer Res. 
Vol.35, pp.2426-2433.  
Obara, W; Mizutani, Y; Oyama, C; et al. (2008). Prospective study of combined treatment 
with interferon-alpha and active vitamin D3 for Japanese patients with metastatic 
renal cell carcinoma. Int J Urol. Vol.15, No.9, pp.794-799. 
Oliveri, MB; Ladizesky, M; Mautalen, CA; et al. (1993). Seasonal variations of 25-
hydroxyvitamin D and parathyroid hormone in Ushuala (Argentina), the 
southernmost city of the world. Bone Miner. Vol.20, pp.99-108. 
Pálmer, HG; González-Sancho, JM; Espada, J; et al. (2001). Vitamin D3 promotes the 
differentiation of colon carcinoma cells by the induction of E-cadherin and the 
inhibition of ┚-catenin signaling. J Cell Biol. Vol.154, No.2, pp.369-387. 
Palmieri-Sevier, A; Palmieri, GM; Baumgartner, CJ; Britt, LG. (1993). Case report: long-term 
remission of parathyroid cancer: possible relation to vitamin D and calcitriol 
therapy. Am J Med Sci. Vol.306, No.5, pp.309-312. 
Perl, AK; Wilgenbus, P; Dahl, U; et al. (1998). A causal role for E-cadherin in the transition 
from adenoma to carcinoma. Nature. Vol.392, pp.190-193. 
Pichaud, F; Roux, S; Frendo, JL; et al. (1997). 1alpha,25-dihydroxyvitamin D3 induces NAD+-
dependent 15-hydroxyprostaglandin dehydrogenase in human neotal monocytes. 
Blood. Vol.89, pp.2105-2112. 
Pilz, S; Dobnig, H; Winklhofer-Roob, B; et al. (2008). Low serum levels of 25-hydroxyvitamin 
D predict fatal cancer in patients referred to coronary angiography. Cancer 
Epidemiol Biomarkers Prev. Vol.17, pp.1228-1233.  
Polverini, PJ. (2002). Angiogenesis in health and disease: insights into basic mechanisms and 
therapeutic opportunities. J Dent Educ. Vol.66, pp.962-975. 
Raina, V; Cunninham, D; Gilchrist, N; Soukop, M. (1991). Alphacalvidol is a nontoxic, 
effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer. Vol.63, 
pp.463-465. 
www.intechopen.com
 
Advances in Cancer Management 
 
14
Reed, KR; Sansom, OJ; Hayes, AJ; et al. (2004). PPARdelta status and Apc-mediated 
tumorigenesis in the mouse intestine. Oncogene. Vol.23, pp.8992-8996. 
Rehder, DS; Nelson, RW; Borges, CR. (2009). Glycosylation status of vitamin D binding 
protein in cancer patients. Protein Science. Vol.18, No.10, pp.2036-2042. 
Ristimaki, A; Sivula, A; Lundin, J; et al. (2002). Prognostic significance of elevated 
cyclooxygenase-2 expression in breast cancer. Cancer Res. Vol.62, pp.632-635. 
Saramäki, A; Banwell, CM; Campbell, MJ; Carlberg, C. (2006). Regulation of the human 
p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the D3 receptor. 
Nucleic Acids Res. Vol.34, pp.543-554. 
Schwartz, GG; Eads, D; Rao, A; et al. (2004). Pancreatic cancer cells express 25-
hydroxyvitamin D-1┙-hydroxylase and their proliferation is inhibited by the 
prohormone 25-hydroxyvitamin D3. Carcinogenesis. Vol.25, No.6, pp.1015-1026. 
Semenza, GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer. Vol.3, pp.721-732. 
Shokravi, MT; Marcus, DM; Alroy, J; et al. (1995). Vitamin D inhibits angiogenesis in 
transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. Vol.36, pp.83-87. 
Skinner, HG, and Schwartz, GG. (2009). The relation of serum parathyroid hormone and 
serum calcium to serum levels of Prostatic-specific antigen: a population-based 
study. Cancer Epidemiol Biomarkers Prev. Vol.18, No.11, pp.2869-2873.  
Slapek, CA; Desforges, JF; Fogaren, T; et al. (1992).Treatment of acute myeloid leukemia in 
the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am J Hematol. 
Vol.41, pp.178-183. 
Slattery, ML; Yakumo, K; Hoffman, M; Neuhausen, S. (2001). Variants of the VDR gene and 
risk of colon cancer (United States). Cancer Causes Control. Vol.12, No.4, pp.359-364. 
Slattery, ML; Sweeney, C; Murtaugh, M; et al. (2006). Associations between vitamin D, 
vitamin D receptor gene and the and the androgen receptor gene with colon and 
rectal cancer. Int J Cancer. Vol.118, No.12, pp.3140-3146. 
Slattery, ML; Curtin, K; Wolff, RK; et al. (2009). A compromise of colon and rectal somatic 
DNA alterations. Dis Colon Rectum. Vol.52, pp.1304-1311. 
Slattery, ML; Wolff, RK; Herrick, JS; et al. (2010). Calcium, vitamin D, VDR genotypes, and 
epigenetic changes in rectal tumors. Nutr Cancer. Vol.62, No.4, pp.436-442. 
Slebos, RJC; Hoppin, JA; Tolbert, PE; et al. (2000). K-ras and p53 in pancreatic cancer: 
association with medical history, histopathology, and environmental exposures in a 
population-based study. Cancer Epidemiol Biomarkers Prev. Vol.9, N0.11, pp.1223-
1232. 
Stambolsky, P; Tabach, Y; Fontemaggi, G; et al. (2010). Modulation of the vitamin D3 
response by cancer-associated mutant p53. Cancer Cell. Vol.17, No.3, pp.273-285. 
Steinbach, G; Lynch, PM; Phillips, RK; et al. (2000). The effect of celecoxib, a cyclooxygenase-
2 inhibitor, in familial adenomatous polyposis. N Engl J Med. Vol.342, pp.1946-1952. 
Steffen, M; Cayre, Y; Manogue, KR; et al. (1988). 1,25-dihydroxyvitamin D3 transcriptionally 
regulates tumour necrosis factor mRNA during HL-60 cell differentiation. 
Immunology. Vol.63, pp.43-46. 
Stryd, RP; Gilbertson, TJ; Bruden, MN. (1979). A seasonal variation study of 25-
hydroxyvitamin D3 serum levels in normal human. J Clin Endocrinol Metab. Vol.48, 
pp.771-775. 
www.intechopen.com
 
Vitamin D and Cancer 
 
15 
Tamez, S; Norizoe, C; Ochiai, K; et al. (2009). Vitamin D receptor polymorphisms and 
prognosis of patients with epithelial ovarian cancer. Br J Cancer. Vol.101, pp.1957-
1960. 
Tangpricha, V; Flanagan, JN; Whitlatch, LW; et al. (2001). 25-hydroxyvitamin D3-1┙-
hydroxylase in normal and malignant colon tissue. Lancet. Vol.357, pp.1673-1674. 
Taylor, JA; Hirvonen, A; Watson, M; et al. (1996). Association of prostate cancer with 
vitamin D receptor gene polymorphisms. Cancer Res. Vol.56, pp.4108-4110. 
Telenius-Berg, M; Almqvist, S; Wästhed, B. (1975). Serum calcitonin response to induce 
hypercalcemia. Acta Med Scand. Vol.197, No.5, pp.367-375. 
Thomas, MG; Tebbutt, S; Williamson, RC. (1992). Vitamin D and its metabolites inhibit cell 
proliferation in human rectal mucosa and a colon cancer cell line. Gut. Vol.33, 
No.12, pp.1660-1663. 
Ting, HJ; Hsu, J; Bao,BY; Lee, YF. (2007). Docetaxel-induced growth inhibition an apoptosis 
in androgen indepenpent prostate cancer cells are enhanced by 1alpha,25-
dihydroxyvitamin D3. Cancer Lett. Vol.247, pp.122-129. 
Trinchierie, G; Rosen, M; Perussia, B. (1987). Induction of differentiation of human myeloid 
cell lines by tumor necrosis factor in cooperation with 1alpha,25-dihydroxyvitamin 
D3. Cancer Res. Vol.47, pp.2236-2242. 
Tumura, M; Gu, J; Tran, H; Yamada, KM. (1999). PTEN gene and integrin signaling in 
cancer. J Natl Cancer Inst. Vol.91, pp.1820-1828. 
Umbas, R; Isaacs, WB; Bringuier, PP; et al. (1994). Decreased E-cadherin expression is 
associated with poor prognosis in patients with prostate cancer. Cancer Res. Vol.54, 
pp.3939-3933.  
Wang, QM; Jones, JP; Studzinski, GP. (1996). Cyclin-dependent kinase inhibitor p27 as a 
mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 
cells. Cancer Res. Vol.56, pp.264-267. 
Wali, RK; Baum, CL; Bolt, MJ; et al. (1992). 1,25-dihydroxyvitamin D3 inhibits Na+-H+ 
exchange by stimulating membrane phosphoinositide turnover and increasing 
cytosolic calcium in CaC0-2 cells. Endocrinology. Vol.131, No.3, pp.1125-1133. 
Weitsman, GE; Ravid, A; Liberman, UA; et al. (2003). Vitamin D enhances caspase-
dependent and independent TNF-induced breast cancer cell death: the role of 
reactive oxygen species. Ann N Y Acad Sci. Vol.1010, pp.437-440. 
Welsh, JE; Zinser, LN; Mianecki-Morton, L; et al. (2011). Age-related changes in the 
epithelial and stromal compartments of the mammary gland in normocalcemic 
mice lacking the vitamin D3 receptor. PLoS One. Vol.6, No.1, p.e16479. 
Yacobi, R; Koren, R; Liberman, UA; et al. (1996). 1alpha,25-dihydroxyvitamin D3 increases 
the sensitivity of human renal carcinoma cells to tumor necrosis factor alpha but 
not to interferon alpha or lymphokine-activated killer cells. J Endocrinol. Vol.149, 
pp.327-333.  
Zabel, M and Dietel, M. (1991). Calcitriol decreases calcitonin secretion from a human 
medullary carcinoma cell line via specific receptor action. Acta Endocrinol (Copenh). 
Vol.125, No.3, pp.299-304. 
Yan, M; Rerko, RM; Platzer, P; et al. (2004). 15-hydroxyprostaglandin dehydrogenase, a 
COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human 
gastrointestinal cancer. PNAS. Vol.101, pp.17468-17473. 
www.intechopen.com
 
Advances in Cancer Management 
 
16
Zinser, GM and Welsh, JE. (2004). Accelerated mammary gland development during 
pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. 
Mol Endocrinol. Vol.18, pp.2208-2223. 
van Rees, BP and Ristimaki, A. (2001). Cyclooxygenase-2 in carcinogenesis of the 
gastrointestinal tract. Scand J Gastrenterol. Vol.36, pp.897-903. 
Vandevalle, B; Hornez, L; Wattez, N; et al. (1995). Vitamin-D3 derivatives and breast-tumor 
cell growth: effect on intracellular calcium and apoptosis. Int J Cancer. Vol.61, pp. 
806-811. 
www.intechopen.com
Advances in Cancer Management
Edited by Prof. Ravinder Mohan
ISBN 978-953-307-870-0
Hard cover, 278 pages
Publisher InTech
Published online 27, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer is now the most common cause of death in the world. However, because of early diagnosis, better
treatment, and advanced life expectancy, many cancer patients frequently live a long, happy, and healthy life
after the diagnosis- and often live as long as patients who eventually do not die because of cancer. This book
presents newer advances in diagnosis and treatment of specific cancers, an evidence-based and realistic
approach to the selection of cancer treatment, and cutting-edge laboratory developments such as the use of
the MALDI technique and computational methods that can be used to detect newer protein biomarkers of
cancers in diagnosis and to evaluate the success of treatment.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Khanh vinh quốc Lương and Lan Thị Hòang Nguyễn (2012). Vitamin D and Cancer, Advances in Cancer
Management, Prof. Ravinder Mohan (Ed.), ISBN: 978-953-307-870-0, InTech, Available from:
http://www.intechopen.com/books/advances-in-cancer-management/vitamin-d-cancer
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
